BCTD: A Drug-Target Relation Database for Drug Repositioning

作者: 王克强 :复旦大学生命科学学院遗传学研究所遗传工程国家重点实验室,上海; 吴宏宇 , 黄青山 :复旦大学生命科学学院遗传学研究所遗传工程国家重点实验室,上海;上海高科联合生物技术研发有限公司,上海; 李国栋 :上海高科联合生物技术研发有限公司,上海;

关键词: 靶点数据库药物重定位Target Database Drug Repositioning


Abstract: Discovering and developing new drug is an arduous, costly and risky process. Drug repositioning, by discovering new indications of old drugs out of their original indications, is a time-saving, cost-efficient and low-risk manner. This made it more and more important in drug discovery and development. It has appeared numerous methods for drug repositioning in recent years. Combining the information of interactions between drugs and targets with omics data is a reasonable and effectively approach of drug repositioning. Dozens of databases including information of drug targets were constructed with varying scopes by different research groups in the past decade. However, it is inconvenient to researchers who need such information because of the lack of coordination in naming rules among these databases and the existed data omissions or redundancies. So we create a new database of drug-target interactions by manually inspecting and standardizing the data collected from these databases and scientific literatures. In the current version, there are 766 drug/compound entries, 746 target entries and 2862 items of drug-target interactions in the database. It will facilitate researchers to get the information of drug targets easily and quickly, providing clues for drug repositioning.


文章引用: 王克强 , 吴宏宇 , 李国栋 , 黄青山 (2015) BCTD:一个药物重定位研究用药物靶点数据库。 计算生物学, 5, 41-47. doi: 10.12677/HJCB.2015.53005


[1] Rask-Andersen, M., Almen, M.S. and Schioth, H.B. (2011) Trends in the exploitation of novel drug targets. Nature Reviews Drug Discovery, 10, 579-590.

[2] Gottleib, S. (2012) Part II—Drug shortages: Big pharma’s new business model. Mo Med, 109, 100-101.

[3] Chong, C.R. and Sullivan Jr., D.J. (2007) New uses for old drugs. Nature, 448, 645-646.

[4] Boolell, M., Allen, M.J., Ballard, S.A., Gepi-Attee, S., Muirhead, G.J., et al. (1996) Sildenafil: An orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. International Journal of Impotence Research, 8, 47-52.

[5] Lamb, J., Crawford, E.D., Peck, D., Modell, J.W., Blat, I.C., et al. (2006) The connectivity map: Using gene-expres- sion signatures to connect small molecules, genes, and disease. Science, 313, 1929-1935.

[6] Sanseau, P., Agarwal, P., Barnes, M.R., Pastinen, T., Richards, J.B., et al. (2012) Use of genome-wide association studies for drug repositioning. Nature Biotechnology, 30, 317-320.

[7] Yang, L. and Agarwal, P. (2011) Systematic drug repositioning based on clinical side-effects. PLoS One, 6, e28025.

[8] Qin, C., Zhang, C., Zhu, F., Xu, F., Chen, S.Y., et al. (2014) Therapeutic target database update 2014: A resource for targeted therapeutics. Nucleic Acids Research, 42, D1118-D1123.

[9] Law, V., Knox, C., Djoumbou, Y., Jewison, T., Guo, A.C., et al. (2014) DrugBank 4.0: Shedding new light on drug metabolism. Nucleic Acids Research, 42, D1091-D1097.

[10] von Eichborn, J., Murgueitio, M.S., Dunkel, M., Koerner, S., Bourne, P.E., et al. (2011) PROMISCUOUS: A database for network-based drug-repositioning. Nucleic Acids Research, 39, D1060-D1066.

[11] Davis, A.P., Grondin, C.J., Lennon-Hopkins, K., Saraceni-Richards, C., Sciaky, D., et al. (2015) The comparative toxicogenomics database’s 10th year anniversary: Update 2015. Nucleic Acids Research, 43, D914-D920.

[12] Gao, Z., Li, H., Zhang, H., Liu, X., Kang, L., et al. (2008) PDTD: A web-accessible protein database for drug target identification. BMC Bioinformatics, 9, 104.

[13] Roider, H.G., Pavlova, N., Kirov, I., Slavov, S., Slavov, T., et al. (2014) Drug2Gene: An exhaustive resource to explore effectively the drug-target relation network. BMC Bioinformatics, 15, 68.

[14] Seiler, K.P., George, G.A., Happ, M.P., Bodycombe, N.E., Carrinski, H.A., et al. (2008) ChemBank: A small-molecule screening and cheminformatics resource database. Nucleic Acids Research, 36, D351-D359.

[15] Bull, S.C. and Doig, A.J. (2015) Properties of protein drug target classes. PLoS ONE, 10, e0117955.

[16] Xu, H., Xu, H., Lin, M., Wang, W., Li, Z., et al. (2007) Learning the drug target-likeness of a protein. Proteomics, 7, 4255-4263.

[17] Drews, J. (2000) Drug discovery: A historical perspective. Science, 287, 1960-1964.

[18] Russ, A.P. and Lampel, S. (2005) The druggable genome: An update. Drug Discovery Today, 10, 1607-1610.

[19] Imming, P., Sinning, C. and Meyer, A. (2006) Drugs, their targets and the nature and number of drug targets. Nature Reviews Drug Discovery, 5, 821-834.

[20] Kuhn, M., Szklarczyk, D., Pletscher-Frankild, S., Blicher, T.H., von Mering, C., et al. (2014) STITCH 4: Integration of protein-chemical interactions with user data. Nucleic Acids Research, 42, D401-D407.